New drug trial offers hope for Tough-to-Treat blood cancers
NCT ID NCT07465835
Summary
This early-stage study is testing a new drug called ELA026 for adults with advanced T cell cancers that have returned or haven't responded to previous treatments. Researchers will first determine safe dosage levels, then expand to more participants to see how well the drug works. The goal is to control the cancer and improve outcomes for patients who have limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START, Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Conditions
Explore the condition pages connected to this study.